News-Medical.Net on MSN8d
New 3D imaging technology could revolutionize medical diagnostics
New technology developed by researchers at the University of Houston could revolutionize medical imaging and lead to faster, ...
PharmiWeb5d
Global MRI Contrast Agents Market to Reach USD 1.23 Billion by 2029 at a 4.4% of CAGR
The MRI contrast agents market is expected to grow 1.3X from 2022 to 2029, reaching USD 1.23 Billion by 2029. Paramagnetic ...
Medscape6d
Advanced MRI Scanner Using Ultra-Low Magnetic Fields Promises Better Cancer Detection
New MRI scanning technology developed at Aberdeen University could improve cancer detection and reduce repeat surgeries by ...
Medscape7d
Echocardiographic Contrast Agents: Safe and Efficacious
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
pharmaphorum8d
Bayer reveals phase 3 data for improved MRI contrast agent
The company has reported the first phase 3 results in hand for gadoquatrane, which reduces the dose of gadolinium delivered ...
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The ...
Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving Sustainability in Medical Imaging
Bracco Imaging SpA, a world leader in diagnostic imaging and Zereau BV, a provider of unique water technology for the ...
Morningstar8d
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Ferumoxtran is an MRI Contrast Agent that may be used to detect lymph node metastases as small as 2 mm in prostate cancer patients. Sanochemia has secured exclusive global commercialization rights ...